XCUR: the cash flow

MyFinsight

EXICURE, INC. (XCUR)

Cash Flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Net income (loss)	-1,828	-2,898	-2,437	389
Depreciation and amortization	49	28	82	132
Equity-based compensation	NaN	1	0	1
Right-of-use asset impairment loss	NaN	0	NaN	NaN
Amortization of right-of-use asset	57	129	-15	104
Change in fair value of contingent consideration	188	1,012	246	295
Gain on early lease termination	0	0	0	5,974
Gain on settlement of accounts payables	0	0	155	191
Loss on disposal/sale of subsidiary	NaN	-98	NaN	NaN
Loss on disposal of assets	-37	0	-4	-86
Income tax benefit	NaN	-634	NaN	NaN
Other receivable	1,459	NaN	-23	-1,434
Accounts receivable	NaN	-1,342	NaN	NaN
Other liabilities	NaN	0	0	0
Prepaid expenses and other current assets	-2	3	127	-169
Other noncurrent assets	NaN	-853	-79	734
Accounts payable	755	404	-530	303
Accrued expenses	-400	-22	-698	106
Net cash used in operating activities	-1,142	-1,147	-3,528	-3,880
Capital expenditures	NaN	-213	-106	320
Proceeds from sale of fixed assets	NaN	0	2	40
Acquisition of gpcr therapeutics usa inc	NaN	2,090	NaN	NaN
Proceeds from sale of subsidiary	NaN	474	NaN	NaN
Cash removed from the sale of kcc	NaN	232	NaN	NaN
Acquisition of gpcr therapeutics usa inc	-2,090	NaN	0	2,090
Net cash used in investing activities	0	455	108	-2,370
Proceeds from short term debt	NaN	0	0	0
Proceeds from common stock offering	0	0	0	1,600
Net cash provided by provided by financing activities	0	0	0	1,600
Net decrease in cash and cash equivalents	-1,142	-692	-3,420	-4,650
Cash and cash equivalents - beginning of period	3,746	4,438	12,508	NaN
Cash and cash equivalents - end of period	2,604	3,746	4,438	NaN

Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.